201 related articles for article (PubMed ID: 8676808)
1. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
Guijarro C; Keane WF
Miner Electrolyte Metab; 1996; 22(1-3):147-52. PubMed ID: 8676808
[TBL] [Abstract][Full Text] [Related]
2. Lipids and progressive renal failure.
Keane WF
Wien Klin Wochenschr; 1996; 108(14):420-4. PubMed ID: 8784983
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis.
Kasiske BL; O'Donnell MP; Kim Y; Atluru D; Keane WF
Kidney Int Suppl; 1994 Feb; 45():S51-3. PubMed ID: 8158898
[TBL] [Abstract][Full Text] [Related]
4. The mevalonate pathway: importance in mesangial cell biology and glomerular disease.
O'Donnell MP; Kasiske BL; Kim Y; Atluru D; Keane WF
Miner Electrolyte Metab; 1993; 19(3):173-9. PubMed ID: 8232104
[TBL] [Abstract][Full Text] [Related]
5. Lovastatin inhibits proliferation of rat mesangial cells.
O'Donnell MP; Kasiske BL; Kim Y; Atluru D; Keane WF
J Clin Invest; 1993 Jan; 91(1):83-7. PubMed ID: 8423236
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin.
Massy ZA; Kim Y; Guijarro C; Kasiske BL; Keane WF; O'Donnell MP
Biochem Biophys Res Commun; 2000 Jan; 267(2):536-40. PubMed ID: 10631097
[TBL] [Abstract][Full Text] [Related]
7. Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells.
Choi JW; Jung SE
J Pharmacol Exp Ther; 1999 Apr; 289(1):572-9. PubMed ID: 10087052
[TBL] [Abstract][Full Text] [Related]
8. Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells.
Guijarro C; Kim Y; Schoonover CM; Massy ZA; O'Donnell MP; Kasiske BL; Keane WF; Kashtan CE
Nephrol Dial Transplant; 1996 Jun; 11(6):990-6. PubMed ID: 8671958
[TBL] [Abstract][Full Text] [Related]
9. Effect of lipids on glomerular injury and progression of renal disease.
Keane WF
Verh K Acad Geneeskd Belg; 1994; 56(2):91-104. PubMed ID: 8048270
[TBL] [Abstract][Full Text] [Related]
10. Collagen secretion and growth of mesangial cells require geranylgeranylpyrophosphate.
Nishimura M; Tanaka T; Yasuda T; Kurakata S; Kitagawa M; Yamada K; Saito Y; Hirai A
Kidney Int; 1999 Feb; 55(2):520-8. PubMed ID: 9987076
[TBL] [Abstract][Full Text] [Related]
11. Effects of fungal statins on high-glucose-induced mouse mesangial cell hypocontractility may involve filamentous actin, t-complex polypeptide 1 subunit beta, and glucose regulated protein 78.
Hwang JC; Chang LC; Lin YF; Shui HA; Chen JS
Transl Res; 2010 Aug; 156(2):80-90. PubMed ID: 20627192
[TBL] [Abstract][Full Text] [Related]
12. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
13. Direct inhibitory effects of simvastatin on matrix accumulation in cultured murine mesangial cells.
Nogaki F; Muso E; Yashiro M; Kasuno K; Kamata T; Ono T; Sasayama S
Kidney Int Suppl; 1999 Jul; 71():S198-201. PubMed ID: 10412775
[TBL] [Abstract][Full Text] [Related]
14. Effect of simvastatin on proliferative nephritis and cell-cycle protein expression.
Yoshimura A; Nemoto T; Sugenoya Y; Inui K; Watanabe S; Inoue Y; Sharif S; Yokota N; Uda S; Morita H; Ideura T
Kidney Int Suppl; 1999 Jul; 71():S84-7. PubMed ID: 10412745
[TBL] [Abstract][Full Text] [Related]
15. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
[TBL] [Abstract][Full Text] [Related]
16. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].
Fujita R; Matsushima T
Nihon Rinsho; 1999 Dec; 57(12):2821-5. PubMed ID: 10638219
[TBL] [Abstract][Full Text] [Related]
17. Effect of pravastatin on type IV collagen secretion and mesangial cell proliferation.
Nishimura M; Tanaka T; Yasuda T; Kurakata S; Kitagawa M; Yamada K; Saito Y; Hirai A
Kidney Int Suppl; 1999 Jul; 71():S97-100. PubMed ID: 10412748
[TBL] [Abstract][Full Text] [Related]
18. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
Flint OP; Masters BA; Gregg RE; Durham SK
Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
[TBL] [Abstract][Full Text] [Related]
20. Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin.
Kim SY; Guijarro C; O'Donnell MP; Kasiske BL; Kim Y; Keane WF
Kidney Int; 1995 Aug; 48(2):363-71. PubMed ID: 7564103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
